Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BAC Bank of America	$34.37 -7.7%	$43.74	$33.67 ▼ $48.08	$261.32B	1.32	37.78 million shs	107.69 million shs
BMY Bristol-Myers Squibb	$55.32 -4.3%	$58.62	$39.35 ▼ $63.33	$112.56B	0.43	12.76 million shs	14.65 million shs
DB Deutsche Bank Aktiengesellschaft	$20.44 -10.7%	$21.90	$13.70 ▼ $25.33	$45.58B	1.03	2.24 million shs	7.21 million shs
HSBC HSBC	$49.87 -6.8%	$56.09	$39.42 ▼ $61.88	$177.57B	0.4	1.69 million shs	5.39 million shs
NVS Novartis	$105.79 -5.8%	$109.02	$92.35 ▼ $120.92	$216.24B	0.56	1.52 million shs	3.52 million shs
PFE Pfizer	$22.99 -5.4%	$25.87	$22.95 ▼ $31.54	$130.39B	0.61	39.46 million shs	79.83 million shs
RDY Dr. Reddy's Laboratories	$12.37 -6.6%	$13.33	$12.36 ▼ $16.89	$10.32B	0.48	1.35 million shs	3.93 million shs
TEVA Teva Pharmaceutical Industries	$13.83 -6.9%	$16.52	$12.51 ▼ $22.80	$15.68B	0.82	9.74 million shs	18.09 million shs
WHR Whirlpool	$85.66 -0.5%	$99.34	$79.70 ▼ $135.49	$4.74B	1.44	1.05 million shs	1.82 million shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BAC Bank of America	-7.62%	-16.64%	-18.69%	-23.29%	-8.19%
BMY Bristol-Myers Squibb	-4.13%	-7.95%	-7.56%	-2.21%	+6.00%
DB Deutsche Bank Aktiengesellschaft	-10.58%	-14.76%	-14.41%	+16.84%	+26.53%
HSBC HSBC	-6.70%	-13.68%	-19.00%	+1.62%	+24.26%
NVS Novartis	-5.85%	-6.12%	-5.42%	+8.35%	+12.09%
PFE Pfizer	-5.37%	-8.77%	-11.33%	-13.54%	-15.57%
RDY Dr. Reddy's Laboratories	-6.55%	-6.27%	-4.24%	-19.90%	-15.40%
TEVA Teva Pharmaceutical Industries	-6.84%	-8.14%	-13.05%	-34.89%	-2.12%
WHR Whirlpool	-0.48%	-4.38%	-6.51%	-25.54%	-26.04%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BAC Bank of America	4.9801 of 5 stars	4.4	3.0	4.2	3.3	2.7	1.7	3.8
BMY Bristol-Myers Squibb	3.7092 of 5 stars	1.2	3.0	4.2	4.0	3.5	3.3	0.0
DB Deutsche Bank Aktiengesellschaft	3.3633 of 5 stars	0.0	5.0	3.3	0.0	2.5	0.0	2.5
HSBC HSBC	2.5624 of 5 stars	0.0	5.0	1.7	0.0	2.0	0.0	2.5
NVS Novartis	2.7739 of 5 stars	1.9	5.0	2.5	0.0	3.3	0.0	1.9
PFE Pfizer	4.9661 of 5 stars	3.3	3.0	4.2	4.2	3.3	3.3	3.1
RDY Dr. Reddy's Laboratories	3.3451 of 5 stars	3.3	4.0	1.7	0.0	3.4	0.0	1.9
TEVA Teva Pharmaceutical Industries	2.3706 of 5 stars	3.4	3.0	0.8	0.0	2.6	0.8	0.6
WHR Whirlpool	3.0303 of 5 stars	1.9	2.0	2.5	1.6	2.5	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BAC Bank of America	2.83	Moderate Buy	$48.31	40.55% Upside
BMY Bristol-Myers Squibb	2.33	Hold	$57.86	4.59% Upside
DB Deutsche Bank Aktiengesellschaft	3.00	Buy	N/A	N/A
HSBC HSBC	2.60	Moderate Buy	N/A	N/A
NVS Novartis	1.80	Reduce	$123.38	16.62% Upside
PFE Pfizer	2.63	Moderate Buy	$31.92	38.86% Upside
RDY Dr. Reddy's Laboratories	2.50	Moderate Buy	$17.00	37.45% Upside
TEVA Teva Pharmaceutical Industries	2.86	Moderate Buy	$23.43	69.40% Upside
WHR Whirlpool	1.75	Reduce	$106.00	23.74% Upside

Current Analyst Ratings Breakdown

Latest BMY, WHR, BAC, DB, HSBC, NVS, PFE, TEVA, and RDY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/4/2025	BAC Bank of America	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$53.00 ➝ $50.00
4/3/2025	BAC Bank of America	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$49.50 ➝ $43.50
4/1/2025	BAC Bank of America	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$51.00 ➝ $48.00
3/27/2025	PFE Pfizer	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/24/2025	DB Deutsche Bank Aktiengesellschaft	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
3/24/2025	BAC Bank of America	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$54.00 ➝ $50.00
3/18/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/12/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/10/2025	PFE Pfizer	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/7/2025	DB Deutsche Bank Aktiengesellschaft	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/7/2025	BAC Bank of America	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 4/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BAC Bank of America	$101.89B	2.56	$3.00 per share	11.45	$35.50 per share	0.97
BMY Bristol-Myers Squibb	$48.30B	2.33	$5.84 per share	9.48	$8.08 per share	6.85
DB Deutsche Bank Aktiengesellschaft	$30.05B	1.35	$4.56 per share	4.48	$43.15 per share	0.47
HSBC HSBC	$67.40B	2.63	$6.99 per share	7.13	$53.68 per share	0.93
NVS Novartis	$51.72B	4.18	$10.55 per share	10.03	$21.59 per share	4.90
PFE Pfizer	$63.63B	2.05	$3.60 per share	6.38	$15.81 per share	1.45
RDY Dr. Reddy's Laboratories	$311.31B	0.03	$0.93 per share	13.25	$4.50 per share	2.75
TEVA Teva Pharmaceutical Industries	$16.54B	0.95	$2.74 per share	5.05	$4.75 per share	2.91
WHR Whirlpool	$16.61B	0.29	$20.30 per share	4.22	$52.96 per share	1.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BAC Bank of America	$27.13B	$3.22	10.67	7.88	1.21	14.10%	10.29%	0.84%	4/15/2025 (Estimated)
BMY Bristol-Myers Squibb	-$8.95B	-$4.42	N/A	9.08	2.07	-18.53%	13.93%	2.46%	4/24/2025 (Estimated)
DB Deutsche Bank Aktiengesellschaft	$3.64B	$1.39	14.70	6.57	N/A	4.66%	3.90%	0.22%	4/24/2025 (Estimated)
HSBC HSBC	$23.53B	$6.20	8.04	7.00	1.05	16.17%	12.20%	0.79%	4/29/2025 (Estimated)
NVS Novartis	$11.94B	$5.88	17.99	12.01	1.70	23.56%	37.24%	15.85%	4/22/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	16.31	7.59	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)
RDY Dr. Reddy's Laboratories	$668M	$0.63	19.69	15.08	N/A	17.25%	17.87%	12.32%	5/6/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.45	N/A	5.26	1.44	-9.91%	42.46%	6.65%	5/7/2025 (Estimated)
WHR Whirlpool	-$323M	-$5.86	N/A	7.97	N/A	-1.95%	21.89%	3.91%	4/23/2025 (Estimated)

Latest BMY, WHR, BAC, DB, HSBC, NVS, PFE, TEVA, and RDY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/29/2025	N/A	HSBC HSBC	$1.60	N/A	N/A	N/A	$16.60 billion	N/A
4/29/2025	N/A	PFE Pfizer	$0.67	N/A	N/A	N/A	$14.43 billion	N/A
4/24/2025	N/A	BMY Bristol-Myers Squibb	$1.55	N/A	N/A	N/A	$10.77 billion	N/A
4/23/2025	N/A	WHR Whirlpool	$1.73	N/A	N/A	N/A	$3.67 billion	N/A
4/22/2025	N/A	NVS Novartis	$2.07	N/A	N/A	N/A	$12.92 billion	N/A
4/15/2025	N/A	BAC Bank of America	$0.80	N/A	N/A	N/A	$26.83 billion	N/A
2/19/2025	Q4 2024	HSBC HSBC	$1.41	$1.45	+$0.04	$0.10	$13.79 billion	$11.56 billion
2/6/2025	Q4 2024	BMY Bristol-Myers Squibb	$1.47	$1.67	+$0.20	$0.04	$11.57 billion	N/A
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion
1/31/2025	Q4 2024	NVS Novartis	$1.80	$1.98	+$0.18	$1.41	$12.86 billion	N/A
1/30/2025	Q4 2024	DB Deutsche Bank Aktiengesellschaft	$0.43	$0.16	-$0.27	$0.16	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BAC Bank of America	$1.04	3.03%	+8.63%	32.30%	11 Years
BMY Bristol-Myers Squibb	$2.48	4.48%	+6.38%	N/A	17 Years
DB Deutsche Bank Aktiengesellschaft	$0.21	1.03%	N/A	15.18%	N/A
HSBC HSBC	$7.18	14.40%	+40.49%	115.81%	N/A
NVS Novartis	$2.51	2.37%	+5.34%	42.69%	N/A
PFE Pfizer	$1.72	7.48%	+2.50%	121.99%	16 Years
RDY Dr. Reddy's Laboratories	$0.08	0.65%	N/A	12.70%	N/A
TEVA Teva Pharmaceutical Industries	$1.01	7.31%	N/A	N/A	N/A
WHR Whirlpool	$7.00	8.17%	+8.70%	N/A	N/A

Latest BMY, WHR, BAC, DB, HSBC, NVS, PFE, TEVA, and RDY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/3/2025	DB Deutsche Bank Aktiengesellschaft	annual	$0.5122	1.7%	5/23/2025	5/26/2025	5/27/2025
3/3/2025	BMY Bristol-Myers Squibb	quarterly	$0.62	4.14%	4/4/2025	4/4/2025	5/1/2025
2/19/2025	HSBC HSBC	quarterly	$1.80	5.8%	3/7/2025	3/7/2025	4/25/2025
1/29/2025	BAC Bank of America	quarterly	$0.26	2.23%	3/7/2025	3/7/2025	3/28/2025
2/17/2025	WHR Whirlpool	quarterly	$1.75	6.73%	2/28/2025	2/28/2025	3/15/2025
2/20/2025	NVS Novartis		$3.8695		3/12/2025	3/12/2025	3/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BAC Bank of America	1.04	0.78	0.78
BMY Bristol-Myers Squibb	2.90	1.25	1.15
DB Deutsche Bank Aktiengesellschaft	1.45	0.74	0.78
HSBC HSBC	0.69	0.88	0.96
NVS Novartis	0.48	1.04	0.84
PFE Pfizer	0.63	1.00	0.73
RDY Dr. Reddy's Laboratories	0.02	1.92	1.38
TEVA Teva Pharmaceutical Industries	2.97	0.98	0.75
WHR Whirlpool	1.62	0.72	0.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BAC Bank of America	70.71%
BMY Bristol-Myers Squibb	76.41%
DB Deutsche Bank Aktiengesellschaft	27.90%
HSBC HSBC	1.48%
NVS Novartis	13.12%
PFE Pfizer	68.36%
RDY Dr. Reddy's Laboratories	3.85%
TEVA Teva Pharmaceutical Industries	54.05%
WHR Whirlpool	90.78%

Insider Ownership

Company	Insider Ownership
BAC Bank of America	0.30%
BMY Bristol-Myers Squibb	0.09%
DB Deutsche Bank Aktiengesellschaft	N/A
HSBC HSBC	0.01%
NVS Novartis	0.01%
PFE Pfizer	0.06%
RDY Dr. Reddy's Laboratories	2.00%
TEVA Teva Pharmaceutical Industries	0.55%
WHR Whirlpool	2.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BAC Bank of America	217,000	7.60 billion	7.65 billion	Optionable
BMY Bristol-Myers Squibb	34,300	2.03 billion	2.03 billion	Optionable
DB Deutsche Bank Aktiengesellschaft	83,000	1.99 billion	N/A	Optionable
HSBC HSBC	220,861	3.56 billion	3.58 billion	Optionable
NVS Novartis	101,700	2.04 billion	2.04 billion	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable
RDY Dr. Reddy's Laboratories	24,800	834.76 million	818.05 million	Optionable
TEVA Teva Pharmaceutical Industries	36,800	1.13 billion	1.13 billion	Optionable
WHR Whirlpool	61,000	55.38 million	54.25 million	Optionable

BMY, WHR, BAC, DB, HSBC, NVS, PFE, TEVA, and RDY Headlines

Recent News About These Companies

Whirlpool Fires 651 Workers At Amana Plant Amid Declining Demand — Details

April 5 at 2:36 PM | msn.com

Whirlpool lays off 651 employees, here’s what the company said

April 5 at 9:36 AM | msn.com

Mass Layoffs at Whirlpool! 651 People Wake Up Jobless: Here’s Why

April 5 at 9:36 AM | msn.com

Tulsa Whirlpool facility temporarily closed as tornado damaged is assessed

April 5 at 4:35 AM | msn.com

Union leaders and Gov. Kim Reynolds weigh in on Whirlpool layoffs

April 5 at 4:35 AM | msn.com

Whirlpool Corporation (WHR) – Jim Cramer’s Take: A Disappointing Stock?

April 5 at 4:35 AM | msn.com

Whirlpool (WHR) Stock Moves -0.53%: What You Should Know

April 5 at 4:35 AM | msn.com

Norges Bank Buys Shares of 641,751 Whirlpool Co. (NYSE:WHR)

April 4 at 3:48 AM | marketbeat.com

Tornado near Owasso flips semi-trailers at Whirlpool plant

April 2 at 11:46 PM | news9.com

Owasso tornado: Whirlpool plant hit, homes, cars destroyed as storm leaves thousands without power in Oklahoma | Photos

April 2 at 11:46 PM | msn.com

Whirlpool in Amana to lay off more than 600 employees

April 2 at 6:45 PM | msn.com

The Michigan Council of Women in Technology Foundation (MCWT) and Whirlpool Foundation Present Girls' STEM Event

April 2 at 1:44 PM | csrwire.com

Whirlpool to lay off hundreds at Amana facility

April 2 at 8:43 AM | msn.com

Whirlpool to lay off one third of its workers in Amana

April 2 at 8:43 AM | radioiowa.com

Whirlpool will lay off 650 people at Amana facility

April 2 at 8:43 AM | thegazette.com

Whirlpool Corp. announces Iowa's largest layoff of 2025 in Amana manufacturing facility

April 2 at 8:43 AM | msn.com

Whirlpool Co. (NYSE:WHR) Shares Sold by Meeder Asset Management Inc.

April 2 at 5:25 AM | marketbeat.com

Tariffs Could Shake Building Industry: Homebuilders, Plumbing, Flooring Face Rising Costs

April 1, 2025 | benzinga.com

Whirlpool Corp (WHR) Partners with MCWT for Girls Rock IT Event

April 1, 2025 | gurufocus.com

BREAKING NEWS: Whirlpool in Amana to Cut Hundreds of Jobs

April 1, 2025 | khak.com

Whirlpool laying off 650 workers in Amana

April 1, 2025 | kwwl.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Archer Aviation Stock Climbs as Midnight eVTOL Nears Reality
By Jeffrey Neal Johnson | March 10, 2025
View Archer Aviation Stock Climbs as Midnight eVTOL Nears Reality
Why Archer Aviation Stock Could Soar After Palantir Partnership
By Jeffrey Neal Johnson | March 20, 2025
View Why Archer Aviation Stock Could Soar After Palantir Partnership
5 Reasons the S&P 500 Could Rebound Strongly in 2025
By Thomas Hughes | April 3, 2025
View 5 Reasons the S&P 500 Could Rebound Strongly in 2025
AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
By Leo Miller | March 14, 2025
View AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Everything About Amazon Stock Signals a Buy—Time to Load Up?
By Sam Quirke | March 20, 2025
View Everything About Amazon Stock Signals a Buy—Time to Load Up?

BMY, WHR, BAC, DB, HSBC, NVS, PFE, TEVA, and RDY Company Descriptions

Bank of America NYSE:BAC

$34.37 -2.85 (-7.65%)

Closing price 04/4/2025 03:59 PM Eastern

Extended Trading

$34.17 -0.20 (-0.59%)

As of 04/4/2025 07:59 PM Eastern

Bank of America Corporation, through its subsidiaries, provides banking and financial products and services for individual consumers, small and middle-market businesses, institutional investors, large corporations, and governments worldwide. It operates in four segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking, and Global Markets. The Consumer Banking segment offers traditional and money market savings accounts, certificates of deposit and IRAs, non-interest and interest-bearing checking accounts, and investment accounts and products; credit and debit cards; residential mortgages, and home equity loans; and direct and indirect loans, such as automotive, recreational vehicle, and consumer personal loans. The GWIM segment provides investment management, brokerage, banking, and trust and retirement products and services; wealth management solutions; and customized solutions, including specialty asset management services. The Global Banking segment offers lending products and services, including commercial loans, leases, commitment facilities, trade finance, and commercial real estate and asset-based lending; treasury solutions, such as treasury management, foreign exchange, short-term investing options, and merchant services; working capital management solutions; debt and equity underwriting and distribution, and merger-related and other advisory services; and fixed-income and equity research, and certain market-based services. The Global Markets segment provides market-making, financing, securities clearing, settlement, and custody services; securities and derivative products; and risk management products using interest rate, equity, credit, currency and commodity derivatives, foreign exchange, fixed-income, and mortgage-related products. Bank of America Corporation was founded in 1784 and is based in Charlotte, North Carolina.

Bristol-Myers Squibb NYSE:BMY

$55.32 -2.50 (-4.32%)

Closing price 04/4/2025 03:59 PM Eastern

Extended Trading

$54.75 -0.57 (-1.03%)

As of 04/4/2025 08:00 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Deutsche Bank Aktiengesellschaft NYSE:DB

$20.43 -2.45 (-10.69%)

Closing price 04/4/2025 03:59 PM Eastern

Extended Trading

$20.49 +0.06 (+0.27%)

As of 04/4/2025 08:00 PM Eastern

Deutsche Bank Aktiengesellschaft, a stock corporation, provides corporate and investment banking, and asset management products and services to private individuals, corporate entities, and institutional clients in Germany, the United Kingdom, rest of Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through Corporate Bank, Investment Bank, Private Bank, and Asset Management segments. The Corporate Bank segment offers cash management, trade finance and lending, trust and agency, and securities services, as well as risk management solutions. The Investment Bank segment provides debt origination, merger and acquisitions, foreign exchange, and equity advisory and origination platform services. The Private Bank segment offers payment and account services, and credit and deposit products, as well as investment advice products, such as environmental, social, and governance products. This segment also provides banking, wealth management, other financial, and postal and parcel services; and supports in planning, managing and investing wealth, financing personal and business interests, and servicing institutional and corporate needs. The Asset Management segment offers investment solutions, such as alternative investments, which include real estate, infrastructure, liquid real assets, and sustainable investments; and various other services, including insurance and pension solutions, asset liability management, portfolio management solutions, and asset allocation advisory to individuals and institutions. Deutsche Bank Aktiengesellschaft was founded in 1870 and is headquartered in Frankfurt am Main, Germany.

HSBC NYSE:HSBC

$49.87 -3.63 (-6.79%)

Closing price 04/4/2025 03:59 PM Eastern

Extended Trading

$49.86 -0.01 (-0.01%)

As of 04/4/2025 07:58 PM Eastern

HSBC Holdings plc provides banking and financial services worldwide. The company operates through Wealth and Personal Banking, Commercial Banking, and Global Banking and Markets segments. The Wealth and Personal Banking segment offers retail banking and wealth products, including current and savings accounts, mortgages and personal loans, credit and debit cards, and local and international payment services; and wealth management services comprising insurance and investment products, global asset management services, investment management, and private wealth solutions. This segment serves personal banking and high net worth individuals. The Commercial Banking segment provides credit and lending, treasury management, payment, cash management, commercial insurance, and investment services; commercial cards; international trade and receivables finance services; foreign exchange products; capital raising services on debt and equity markets; and advisory services. It serves small and medium sized enterprises, mid-market enterprises, and corporates. The Global Banking and Markets segment offers financing, advisory, and transaction services; and credit, rates, foreign exchange, equities, money markets, and securities services; and engages in principal investment activities. It serves government, corporate and institutional clients, and private investors. HSBC Holdings plc was founded in 1865 and is headquartered in London, the United Kingdom.

Novartis NYSE:NVS

$105.79 -6.47 (-5.76%)

Closing price 04/4/2025 03:59 PM Eastern

Extended Trading

$104.12 -1.67 (-1.58%)

As of 04/4/2025 07:52 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Pfizer NYSE:PFE

$22.99 -1.30 (-5.35%)

Closing price 04/4/2025 03:59 PM Eastern

Extended Trading

$22.94 -0.05 (-0.22%)

As of 04/4/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Dr. Reddy's Laboratories NYSE:RDY

$12.37 -0.87 (-6.59%)

Closing price 04/4/2025 03:59 PM Eastern

Extended Trading

$12.36 0.00 (-0.02%)

As of 04/4/2025 05:35 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Teva Pharmaceutical Industries NYSE:TEVA

$13.83 -1.02 (-6.87%)

Closing price 04/4/2025 03:59 PM Eastern

Extended Trading

$13.78 -0.04 (-0.33%)

As of 04/4/2025 07:42 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Whirlpool NYSE:WHR

$85.66 -0.46 (-0.53%)

Closing price 04/4/2025 03:59 PM Eastern

Extended Trading

$87.00 +1.34 (+1.56%)

As of 04/4/2025 07:52 PM Eastern

Whirlpool Corporation manufactures and markets home appliances and related products and services in the North America, Europe, the Middle East, Africa, Latin America, and Asia. The company's principal products include refrigerators, freezers, ice makers, and refrigerator water filters; laundry appliances, and commercial laundry products and related laundry accessories; cooking and other small domestic appliances; and dishwasher appliances and related accessories, as well as mixers. It markets and distributes its products primarily under the Whirlpool, Maytag, KitchenAid, JennAir, Consul, Brastemp, Amana, Bauknecht, Hotpoint, Indesit, InSinkErator, Yummly, Affresh, Gladiator, Swash, everydrop, Ignis, Privileg, Eslabon de Lujo, and Acros brands. The company sells its products to retailers, distributors, dealers, builders, and other manufacturers, as well as directly to consumers. Whirlpool Corporation was founded in 1911 and is headquartered in Benton Harbor, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMY, WHR, BAC, DB, HSBC, NVS, PFE, TEVA, and RDY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMY, WHR, BAC, DB, HSBC, NVS, PFE, TEVA, and RDY Earnings

Compare Dividends

Latest BMY, WHR, BAC, DB, HSBC, NVS, PFE, TEVA, and RDY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMY, WHR, BAC, DB, HSBC, NVS, PFE, TEVA, and RDY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BMY, WHR, BAC, DB, HSBC, NVS, PFE, TEVA, and RDY Company Descriptions

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools